Physician profile
Dawson Lim
NPI 1356304513
$3,783.69
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,395 · 2020: $591 · 2021: $749 · 2022: $47.88.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $338.49 | 2019-2021 | |
| Amgen INC. | $290.52 | 2019-2021 | |
| Seagen INC. | $244.85 | 2019-2021 | |
| Pfizer INC. | $244.78 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $240.55 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $222.14 | 2019-2020 | |
| Astellas Pharma US INC | $218.62 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $196.22 | 2019-2021 | |
| Lilly USA, LLC | $164.65 | 2019-2022 | |
| Genentech USA, INC. | $164.43 | 2019-2020 | |
| Genzyme Corporation | $124.35 | 2019-2021 | |
| Janssen Biotech, INC. | $114.57 | 2019-2020 | |
| Eisai INC. | $106.20 | 2019-2021 | |
| Celgene Corporation | $103.87 | 2019-2021 | |
| Incyte Corporation | $95.67 | 2019-2021 |
Show all 41 companies
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawson Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.